Christopher Weidenmaier

Christopher Weidenmaier is a Chief Scientific Officer at mbiomics GmbH and was previously the Director of Research and Head of Host Cell Biology/Immunology at Finch Therapeutics Group. With a strong background in microbiome therapeutics, Christopher has also worked as an Assoc Director of Host Cell Biology and a Principal Investigator at the Hospital of the University of Tübingen. Christopher has a PhD in Biology and has conducted research on the role of cell wall teichoic acids in bacterial infections.